Pleural involvement in lung cancer

被引:52
作者
Agalioti, Theodora [1 ]
Giannou, Anastasios D. [1 ]
Stathopoulos, Georgios T. [1 ]
机构
[1] Univ Patras, Fac Med, Dept Physiol, Lab Mol Resp Carcinogenesis, GR-26504 Patras, Greece
关键词
Lung cancer; pleural membranes; visceral pleural invasion (VPI); malignant pleural effusion (MPE); EGFR mutations; FACTOR-RECEPTOR MUTATIONS; TYROSINE KINASE INHIBITOR; EGFR MUTATION; KRAS MUTATIONS; CLINICAL-PRACTICE; LAVAGE CYTOLOGY; EFFUSION; RESISTANCE; INVASION; ADENOCARCINOMA;
D O I
10.3978/j.issn.2072-1439.2015.04.23
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
The pleural space, a sterile secluded environment in the thoracic cavity, represents an attractive metastatic site for various cancers of lung, breast and gastrointestinal origins. Whereas lung and breast adenocarcinomas could invade the pleural space because of their anatomic proximity, "distant" cancers like ovarian or gastrointestinal tract adenocarcinomas may employ more active mechanisms to the same end. A pleural metastasis is often accompanied by a malignant pleural effusion (MPE), an unfavorable complication that severely restricts the quality of life and expectancy of the cancer patient. MPE is the net "product" of three different processes, namely inflammation, enhanced angiogenesis and vascular leakage. Current efforts are focusing on the identification of cancer cell autocrine (specific mutation spectra and biochemical pathways) and paracrine (cytokine and chemokine signals) characteristics as well as host features (immunological or other) that underlie the MPE phenotype. Herein we examine the pleural histology, cytology and molecular characteristics that make the pleural cavity an attractive metastasis destination for lung adenocarcinoma. Mesothelial and tumor features that may account for the tumor's ability to invade the pleural space are highlighted. Finally, possible therapeutic interventions specifically targeting MPE are discussed.
引用
收藏
页码:1021 / 1030
页数:10
相关论文
共 69 条
  • [1] Detection of EGFR gene mutation in lung cancer by mutant-enriched polymerase chain reaction assay
    Asano, H
    Toyooka, S
    Tokumo, M
    Ichimura, K
    Aoe, K
    Ito, S
    Tsukuda, K
    Ouchida, M
    Aoe, M
    Katayama, H
    Hiraki, A
    Sugi, K
    Kiura, K
    Date, H
    Shimizu, N
    [J]. CLINICAL CANCER RESEARCH, 2006, 12 (01) : 43 - 48
  • [2] The Role of Vascular Endothelial Growth Factor in the Pathogenesis, Diagnosis and Treatment of Malignant Pleural Effusion
    Bradshaw, Michael
    Mansfield, Aaron
    Peikert, Tobias
    [J]. CURRENT ONCOLOGY REPORTS, 2013, 15 (03) : 207 - 216
  • [3] Prospective Molecular Marker Analyses of EGFR and KRAS From a Randomized, Placebo-Controlled Study of Erlotinib Maintenance Therapy in Advanced Non-Small-Cell Lung Cancer
    Brugger, Wolfram
    Triller, Nadja
    Blasinska-Morawiec, Maria
    Curescu, Stefan
    Sakalauskas, Raimundas
    Manikhas, Georgy Moiseevich
    Mazieres, Julien
    Whittom, Renaud
    Ward, Carol
    Mayne, Karen
    Trunzer, Kerstin
    Cappuzzo, Federico
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (31) : 4113 - 4120
  • [4] The Intricate Role of CXCR4 in Cancer
    Chatterjee, Samit
    Azad, Babak Behnam
    Nimmagadda, Sridhar
    [J]. EMERGING APPLICATIONS OF MOLECULAR IMAGING TO ONCOLOGY, 2014, 124 : 31 - 82
  • [5] The quest to overcome resistance to EGFR-targeted therapies in cancer
    Chong, Curtis R.
    Jaenne, Pasi A.
    [J]. NATURE MEDICINE, 2013, 19 (11) : 1389 - 1400
  • [6] Choughule A, 2014, BJC, P1
  • [7] Comprehensive molecular profiling of lung adenocarcinoma
    Collisson, Eric A.
    Campbell, Joshua D.
    Brooks, Angela N.
    Berger, Alice H.
    Lee, William
    Chmielecki, Juliann
    Beer, David G.
    Cope, Leslie
    Creighton, Chad J.
    Danilova, Ludmila
    Ding, Li
    Getz, Gad
    Hammerman, Peter S.
    Hayes, D. Neil
    Hernandez, Bryan
    Herman, James G.
    Heymach, John V.
    Jurisica, Igor
    Kucherlapati, Raju
    Kwiatkowski, David
    Ladanyi, Marc
    Robertson, Gordon
    Schultz, Nikolaus
    Shen, Ronglai
    Sinha, Rileen
    Sougnez, Carrie
    Tsao, Ming-Sound
    Travis, William D.
    Weinstein, John N.
    Wigle, Dennis A.
    Wilkerson, Matthew D.
    Chu, Andy
    Cherniack, Andrew D.
    Hadjipanayis, Angela
    Rosenberg, Mara
    Weisenberger, Daniel J.
    Laird, Peter W.
    Radenbaugh, Amie
    Ma, Singer
    Stuart, Joshua M.
    Byers, Lauren Averett
    Baylin, Stephen B.
    Govindan, Ramaswamy
    Meyerson, Matthew
    Rosenberg, Mara
    Gabriel, Stacey B.
    Cibulskis, Kristian
    Sougnez, Carrie
    Kim, Jaegil
    Stewart, Chip
    [J]. NATURE, 2014, 511 (7511) : 543 - 550
  • [8] Molecular mechanisms of resistance in epidermal growth factor receptor-mutant lung adenocarcinomas
    Cortot, Alexis B.
    Jaenne, Pasi A.
    [J]. EUROPEAN RESPIRATORY REVIEW, 2014, 23 (133) : 356 - 366
  • [9] Clinicopathological predictors of EGFR/KRAS mutational status in primary lung adenocarcinomas
    Dacic, Sanja
    Shuai, Yongli
    Yousem, Samuel
    Ohori, Paul
    Nikiforova, Marina
    [J]. MODERN PATHOLOGY, 2010, 23 (02) : 159 - 168
  • [10] Visceral Pleural Invasion Is Not Predictive of Survival in Patients With Lung Cancer and Smaller Tumor Size
    David, Elizabeth
    Thall, Peter F.
    Kalhor, Neda
    Hofstetter, Wayne L.
    Rice, David C.
    Roth, Jack A.
    Swisher, Stephen G.
    Walsh, Garrett L.
    Vaporciyan, Ara A.
    Wei, Caimea
    Mehran, Reza J.
    [J]. ANNALS OF THORACIC SURGERY, 2013, 95 (06) : 1872 - 1877